Comparative efficacy of ceftriaxone in experimental infections involving bacteroides fragilis and escherichia coli

Manoucher Dezfulian, Roger A. Bitar, John Bartlett

Research output: Contribution to journalArticle

Abstract

The in vivo activity of ceftriaxone was examined in an experimentally induced subcutaneous infection involving Bacteroides fragilis and Escherichia coli. Mice were challenged with 1 of 10 strains of B. fragilis or E. coli, or a dual combination of the two species. The efficacy was measured by a reduction in the count of viable organisms when antimicrobial treatment was initiated 1 h after challenge and continued for 5 days. Ceftriaxone exhibited impressive activity against E. coli but showed poor in vivo activity versus B. fragilis. The antimicrobial activity of ceftriaxone was influenced by the microbial interaction in our dualisolate model. Pharmacokinetic studies showed that ceftriaxone penetrated into abscesses and achieved peak levels of about 40% of the peak serum levels. However, in abscesses infected with B. fragilis nearly all biological activity of ceftriaxone was lost.

Original languageEnglish (US)
Pages (from-to)355-360
Number of pages6
JournalChemotherapy
Volume39
Issue number5
DOIs
StatePublished - 1993

Fingerprint

Bacteroides fragilis
Ceftriaxone
Escherichia coli
Infection
Abscess
Microbial Interactions
Pharmacokinetics
Serum

Keywords

  • Bacteroides fragilis
  • Ceftriaxone
  • Escherichia coli
  • In vivo efficacy
  • Pharmacokinetics
  • Subcutaneous abscess

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Comparative efficacy of ceftriaxone in experimental infections involving bacteroides fragilis and escherichia coli. / Dezfulian, Manoucher; Bitar, Roger A.; Bartlett, John.

In: Chemotherapy, Vol. 39, No. 5, 1993, p. 355-360.

Research output: Contribution to journalArticle

@article{fc97c42349804d7e8f588fc95ef4d27b,
title = "Comparative efficacy of ceftriaxone in experimental infections involving bacteroides fragilis and escherichia coli",
abstract = "The in vivo activity of ceftriaxone was examined in an experimentally induced subcutaneous infection involving Bacteroides fragilis and Escherichia coli. Mice were challenged with 1 of 10 strains of B. fragilis or E. coli, or a dual combination of the two species. The efficacy was measured by a reduction in the count of viable organisms when antimicrobial treatment was initiated 1 h after challenge and continued for 5 days. Ceftriaxone exhibited impressive activity against E. coli but showed poor in vivo activity versus B. fragilis. The antimicrobial activity of ceftriaxone was influenced by the microbial interaction in our dualisolate model. Pharmacokinetic studies showed that ceftriaxone penetrated into abscesses and achieved peak levels of about 40{\%} of the peak serum levels. However, in abscesses infected with B. fragilis nearly all biological activity of ceftriaxone was lost.",
keywords = "Bacteroides fragilis, Ceftriaxone, Escherichia coli, In vivo efficacy, Pharmacokinetics, Subcutaneous abscess",
author = "Manoucher Dezfulian and Bitar, {Roger A.} and John Bartlett",
year = "1993",
doi = "10.1159/000239147",
language = "English (US)",
volume = "39",
pages = "355--360",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Comparative efficacy of ceftriaxone in experimental infections involving bacteroides fragilis and escherichia coli

AU - Dezfulian, Manoucher

AU - Bitar, Roger A.

AU - Bartlett, John

PY - 1993

Y1 - 1993

N2 - The in vivo activity of ceftriaxone was examined in an experimentally induced subcutaneous infection involving Bacteroides fragilis and Escherichia coli. Mice were challenged with 1 of 10 strains of B. fragilis or E. coli, or a dual combination of the two species. The efficacy was measured by a reduction in the count of viable organisms when antimicrobial treatment was initiated 1 h after challenge and continued for 5 days. Ceftriaxone exhibited impressive activity against E. coli but showed poor in vivo activity versus B. fragilis. The antimicrobial activity of ceftriaxone was influenced by the microbial interaction in our dualisolate model. Pharmacokinetic studies showed that ceftriaxone penetrated into abscesses and achieved peak levels of about 40% of the peak serum levels. However, in abscesses infected with B. fragilis nearly all biological activity of ceftriaxone was lost.

AB - The in vivo activity of ceftriaxone was examined in an experimentally induced subcutaneous infection involving Bacteroides fragilis and Escherichia coli. Mice were challenged with 1 of 10 strains of B. fragilis or E. coli, or a dual combination of the two species. The efficacy was measured by a reduction in the count of viable organisms when antimicrobial treatment was initiated 1 h after challenge and continued for 5 days. Ceftriaxone exhibited impressive activity against E. coli but showed poor in vivo activity versus B. fragilis. The antimicrobial activity of ceftriaxone was influenced by the microbial interaction in our dualisolate model. Pharmacokinetic studies showed that ceftriaxone penetrated into abscesses and achieved peak levels of about 40% of the peak serum levels. However, in abscesses infected with B. fragilis nearly all biological activity of ceftriaxone was lost.

KW - Bacteroides fragilis

KW - Ceftriaxone

KW - Escherichia coli

KW - In vivo efficacy

KW - Pharmacokinetics

KW - Subcutaneous abscess

UR - http://www.scopus.com/inward/record.url?scp=0027213761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027213761&partnerID=8YFLogxK

U2 - 10.1159/000239147

DO - 10.1159/000239147

M3 - Article

VL - 39

SP - 355

EP - 360

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 5

ER -